PACB Pacific Biosciences Of California Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PACB

Price (delayed)

$1.675

Market cap

$520.26M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$1.17B

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 28

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a ...

Highlights
Pacific Biosciences Of California's gross profit has surged by 144% YoY and by 31% QoQ
The gross margin has soared by 131% YoY and by 31% from the previous quarter
The quick ratio has contracted by 17% YoY but it has grown by 8% from the previous quarter
The company's equity has shrunk by 97% YoY and by 56% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: http://www.pacb.com
Peers: ILMN GE TMO

Key stats

What are the main financial stats of PACB

PACB stock price

How has the Pacific Biosciences Of California stock price performed over time
Intraday
-3.18%
1 week
27.86%
1 month
12.42%
1 year
35.08%
YTD
-10.43%
QTD
26.89%

Financial performance

How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$160.03M
Gross profit
$59.99M
Operating income
-$133.28M
Net income
-$128.58M
Gross margin
37.5%
Net margin
-80.3%
Pacific Biosciences Of California's gross profit has surged by 144% YoY and by 31% QoQ
The gross margin has soared by 131% YoY and by 31% from the previous quarter
PACB's operating margin has surged by 85% year-on-year and by 77% since the previous quarter
The company's operating income has surged by 84% YoY and by 77% QoQ

Price vs fundamentals

How does PACB's price correlate with its fundamentals

Growth

What is Pacific Biosciences Of California's growth rate over time

Valuation

What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
213.8
P/S
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.29
The EPS has soared by 81% YoY and by 76% from the previous quarter
The company's equity has shrunk by 97% YoY and by 56% QoQ
The price to sales (P/S) is 76% lower than the 5-year quarterly average of 14.0 but 23% higher than the last 4 quarters average of 2.7
The revenue has increased by 5% YoY

Efficiency

How efficient is Pacific Biosciences Of California business performance
The ROE has plunged by 187% YoY but it has soared by 57% from the previous quarter
The ROS has soared by 82% YoY and by 78% from the previous quarter
The company's return on invested capital has surged by 77% YoY and by 77% QoQ
PACB's ROA has soared by 76% from the previous quarter and by 69% YoY

Dividends

What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PACB.

Financial health

How did Pacific Biosciences Of California financials performed over time
The quick ratio has contracted by 17% YoY but it has grown by 8% from the previous quarter
The company's current ratio fell by 15% YoY but it rose by 10% QoQ
The company's debt to equity has surged by 126% QoQ
The company's equity has shrunk by 97% YoY and by 56% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.